Pliant Therapeutics (PLRX) director receives 70,000 stock options at $1.14

Rhea-AI Filing Summary

Pliant Therapeutics director Steve E. Krognes received a compensation-related stock option grant. He was awarded options to purchase 70,000 shares of Pliant Therapeutics common stock at an exercise price of $1.14 per share, expiring on June 11, 2036.

According to the vesting schedule, 25% of the option vests and becomes exercisable on each of October 1, 2026, January 1, 2027, and April 1, 2027. The remaining 25% vests on the earlier of the one-year anniversary of the June 11, 2026 grant date or the next annual meeting of stockholders, provided he continues to serve as a director through the applicable dates.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Krognes Steve E.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	70,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 70,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 70,000 options Exercise price: $1.14 per share Underlying shares: 70,000 shares +3 more

6 metrics

Option grant size 70,000 options Stock Option (Right to Buy) granted to director

Exercise price $1.14 per share Conversion or exercise price of stock options

Underlying shares 70,000 shares Common stock underlying the options

Post-grant derivative holdings 70,000 options Total derivative securities following transaction

Option expiration June 11, 2036 Expiration date of granted options

Initial vesting date October 1, 2026 First 25% of options vest and become exercisable

Key Terms

Stock Option (Right to Buy), grant/award acquisition, exercise price, vesting, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

grant/award acquisition financial

"transaction_action: grant/award acquisition"

exercise price financial

"conversion_or_exercise_price: 1.1400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"25% of the shares subject to such option vest and become exercisable"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

annual meeting of stockholders regulatory

"the earlier of (i) the one-year anniversary ... or (ii) the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krognes Steve E.

(Last) (First) (Middle)

C/O PLIANT THERAPEUTICS, INC.

331 OYSTER POINT BOULEVARD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PLIANT THERAPEUTICS, INC. [ PLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.14	06/11/2026		A		70,000		(1)	06/11/2036	Common Stock	70,000	$0	70,000	D

Explanation of Responses:

1. 25% of the shares subject to such option vest and become exercisable on October 1, 2026, January 1, 2027, and April 1, 2027, respectively, and the remaining 25% of the shares subject to such option vest and become exercisable on the earlier of (i) the one-year anniversary of the June 11, 2026 grant date or (ii) the next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer as a Director through each such date or, if earlier, such annual meeting.

Remarks:

	/s/ Jennifer Woo, attorney-in-fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did PLIANT THERAPEUTICS (PLRX) report for Steve E. Krognes?

Pliant Therapeutics reported a grant of stock options to director Steve E. Krognes. He received options for 70,000 shares of common stock as part of a compensation-related award.

How many PLIANT THERAPEUTICS (PLRX) shares are covered by Steve Krognes’ new options?

The new stock option grant to Steve Krognes covers 70,000 shares of Pliant Therapeutics common stock. These options give him the right to buy those shares once they vest and are exercisable.

What is the exercise price of Steve Krognes’ PLRX stock options?

The exercise price for Steve Krognes’ stock options is $1.14 per share. This is the fixed price at which he can purchase Pliant Therapeutics common stock once the options vest and are exercised.

When do Steve Krognes’ PLIANT THERAPEUTICS (PLRX) options vest?

The options vest in four equal 25% installments. They become exercisable on October 1, 2026, January 1, 2027, April 1, 2027, and the earlier of June 11, 2027 or the next annual stockholder meeting.

What is the expiration date of Steve Krognes’ PLRX stock option grant?

Steve Krognes’ stock options expire on June 11, 2036. After that date, any unexercised options will no longer be usable to purchase Pliant Therapeutics common shares at the stated exercise price.